231 related articles for article (PubMed ID: 25333506)
1. Superior long-term repopulating capacity of G-CSF+plerixafor-mobilized blood: implications for stem cell gene therapy by studies in the Hbb(th-3) mouse model.
Psatha N; Sgouramali E; Gkountis A; Siametis A; Baliakas P; Constantinou V; Athanasiou E; Arsenakis M; Anagnostopoulos A; Papayannopoulou T; Stamatoyannopoulos G; Yannaki E
Hum Gene Ther Methods; 2014 Dec; 25(6):317-27. PubMed ID: 25333506
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major.
Yannaki E; Karponi G; Zervou F; Constantinou V; Bouinta A; Tachynopoulou V; Kotta K; Jonlin E; Papayannopoulou T; Anagnostopoulos A; Stamatoyannopoulos G
Hum Gene Ther; 2013 Oct; 24(10):852-60. PubMed ID: 24001178
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy.
Karponi G; Psatha N; Lederer CW; Adair JE; Zervou F; Zogas N; Kleanthous M; Tsatalas C; Anagnostopoulos A; Sadelain M; Rivière I; Stamatoyannopoulos G; Yannaki E
Blood; 2015 Jul; 126(5):616-9. PubMed ID: 26089395
[TBL] [Abstract][Full Text] [Related]
4. Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor.
Uchida N; Bonifacino A; Krouse AE; Metzger ME; Csako G; Lee-Stroka A; Fasano RM; Leitman SF; Mattapallil JJ; Hsieh MM; Tisdale JF; Donahue RE
Exp Hematol; 2011 Jul; 39(7):795-805. PubMed ID: 21549175
[TBL] [Abstract][Full Text] [Related]
5. Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF.
Lundqvist A; Smith AL; Takahashi Y; Wong S; Bahceci E; Cook L; Ramos C; Tawab A; McCoy JP; Read EJ; Khuu HM; Bolan CD; Joo J; Geller N; Leitman SF; Calandra G; Dunbar C; Kurlander R; Childs RW
J Immunol; 2013 Dec; 191(12):6241-9. PubMed ID: 24244025
[TBL] [Abstract][Full Text] [Related]
6. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
7. Impact of donor hematopoietic cells mobilized with G-CSF and plerixafor on murine acute graft-versus-host-disease.
Arbez J; Saas P; Lamarthée B; Malard F; Couturier M; Mohty M; Gaugler B
Cytotherapy; 2015 Jul; 17(7):948-55. PubMed ID: 25813681
[TBL] [Abstract][Full Text] [Related]
8. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN
Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
[TBL] [Abstract][Full Text] [Related]
9. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
10. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.
Gattillo S; Marktel S; Rizzo L; Malato S; Malabarba L; Coppola M; Assanelli A; Milani R; De Freitas T; Corti C; Bellio L; Ciceri F
Transfusion; 2015 Aug; 55(8):1993-2000. PubMed ID: 25721167
[TBL] [Abstract][Full Text] [Related]
11. Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.
Teipel R; Oelschlägel U; Wetzko K; Schmiedgen M; Kramer M; Rücker-Braun E; Hölig K; von Bonin M; Heidrich K; Fuchs A; Ordemann R; Kroschinsky F; Bornhäuser M; Hütter G; Schmidt H; Ehninger G; Schetelig J; Heidenreich F
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2171-2177. PubMed ID: 29935214
[TBL] [Abstract][Full Text] [Related]
12. Mobilization of hematopoietic stem cells in a thalassemic mouse model: implications for human gene therapy of thalassemia.
Yannaki E; Psatha N; Athanasiou E; Karponi G; Constantinou V; Papadopoulou A; Tasouli A; Kaloyannidis P; Batsis I; Arsenakis M; Anagnostopoulos A; Fassas A
Hum Gene Ther; 2010 Mar; 21(3):299-310. PubMed ID: 19795976
[TBL] [Abstract][Full Text] [Related]
13. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates.
Larochelle A; Krouse A; Metzger M; Orlic D; Donahue RE; Fricker S; Bridger G; Dunbar CE; Hematti P
Blood; 2006 May; 107(9):3772-8. PubMed ID: 16439684
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects.
Yannaki E; Papayannopoulou T; Jonlin E; Zervou F; Karponi G; Xagorari A; Becker P; Psatha N; Batsis I; Kaloyannidis P; Tahynopoulou V; Constantinou V; Bouinta A; Kotta K; Athanassiadou A; Anagnostopoulos A; Fassas A; Stamatoyannopoulos G
Mol Ther; 2012 Jan; 20(1):230-8. PubMed ID: 21952171
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood progenitor cells mobilized by recombinant human granulocyte colony-stimulating factor plus recombinant rat stem cell factor contain long-term engrafting cells capable of cellular proliferation for more than two years as shown by serial transplantation in mice.
Yan XQ; Hartley C; McElroy P; Chang A; McCrea C; McNiece I
Blood; 1995 May; 85(9):2303-7. PubMed ID: 7537109
[TBL] [Abstract][Full Text] [Related]
16. Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?
Serin I; Sevindik OG; Balik Aydin B; Melek E; Mutlu YG; Bilgen H; Bekoz H; Kaynar L
Transfus Apher Sci; 2023 Dec; 62(6):103809. PubMed ID: 37690861
[TBL] [Abstract][Full Text] [Related]
17. FLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome.
He S; Chu J; Vasu S; Deng Y; Yuan S; Zhang J; Fan Z; Hofmeister CC; He X; Marsh HC; Devine SM; Yu J
Biol Blood Marrow Transplant; 2014 Mar; 20(3):309-13. PubMed ID: 24365795
[TBL] [Abstract][Full Text] [Related]
18. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures.
Donahue RE; Jin P; Bonifacino AC; Metzger ME; Ren J; Wang E; Stroncek DF
Blood; 2009 Sep; 114(12):2530-41. PubMed ID: 19602709
[TBL] [Abstract][Full Text] [Related]
19. Effect of FLT3 ligand and granulocyte colony-stimulating factor on expansion and mobilization of facilitating cells and hematopoietic stem cells in mice: kinetics and repopulating potential.
Neipp M; Zorina T; Domenick MA; Exner BG; Ildstad ST
Blood; 1998 Nov; 92(9):3177-88. PubMed ID: 9787154
[TBL] [Abstract][Full Text] [Related]
20. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells.
Ramirez P; Rettig MP; Uy GL; Deych E; Holt MS; Ritchey JK; DiPersio JF
Blood; 2009 Aug; 114(7):1340-3. PubMed ID: 19571319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
